• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过组织微阵列分析筛查转移性肾上腺皮质癌的预后生物标志物，确定P53为总生存期的独立预后标志物。

Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival.

作者信息

Hescot Segolene, Faron Matthieu, Kordahi Manal, Do Cao Christine, Naman Annabelle, Lamartina Livia, Hadoux Julien, Leboulleux Sophie, Pattou Francois, Aubert Sébastien, Scoazec Jean-Yves, Al Ghuzlan Abir, Baudin Eric

机构信息

Department of Nuclear Medicine, Institut Curie, 92210 Saint Cloud, France.

Department of Surgery, Gustave Roussy, 94805 Villejuif, France.

出版信息

Cancers (Basel). 2022 Apr 29;14(9):2225. doi: 10.3390/cancers14092225.

DOI:10.3390/cancers14092225
PMID:35565353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9099575/
Abstract

Advanced adrenocortical carcinoma (ACC) has poor but heterogeneous prognosis. Apart from Ki67 index, no prognostic or predictive biomarker has been validated in advanced ACC, so far. We aimed at analyzing expression of a large panel of proteins involved in known altered pathways in ACC (cell cycle, Wnt/ß-catenin, methylation) to identify and prioritize potential prognostic or predictive parameters metastatic ACC population. We conducted a retrospective multicentric study. Overall survival (OS) and partial response according to RECIST 1.1 were primary endpoints. TMA was set up and 16 markers were analyzed. Modified ENSAT and GRAS parameters were characterized for prognostic adjustment. Results: We included 66 patients with a mean age at metastatic diagnosis of 48.7 ± 15.5 years. Median survival was 27.8 months. After adjustment to mENSAT-GRAS parameters, p53 and PDxK were prognostic of OS. No potential biomarker has been identified as predictive factor of response. We identified for the first time P53 as an independent prognostic marker of metastatic adrenocortical carcinoma after mENSAT-GRAS parameter adjustment. Prognostic impact of Wnt/ß-catenin alterations was not confirmed in this cohort of metastatic ACC.

摘要

晚期肾上腺皮质癌（ACC）预后较差且存在异质性。迄今为止，除Ki67指数外，尚无预后或预测生物标志物在晚期ACC中得到验证。我们旨在分析一大组参与ACC已知改变通路（细胞周期、Wnt/β-连环蛋白、甲基化）的蛋白质的表达，以识别转移性ACC人群潜在的预后或预测参数并进行优先级排序。我们开展了一项回顾性多中心研究。总生存期（OS）和根据RECIST 1.1标准评估的部分缓解率为主要终点。构建了组织微阵列（TMA）并分析了16种标志物。对改良的ENSAT和GRAS参数进行特征分析以用于预后调整。结果：我们纳入了66例患者，转移诊断时的平均年龄为48.7±15.5岁。中位生存期为27.8个月。在根据mENSAT-GRAS参数进行调整后，p53和PDxK对OS具有预后价值。未发现有潜在生物标志物可作为反应的预测因素。我们首次确定在mENSAT-GRAS参数调整后，P53是转移性肾上腺皮质癌的独立预后标志物。在该转移性ACC队列中未证实Wnt/β-连环蛋白改变的预后影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/256f6c01b0c9/cancers-14-02225-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/29ffabd414a6/cancers-14-02225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/09b5fc9d3fad/cancers-14-02225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/277f01a18f60/cancers-14-02225-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/256f6c01b0c9/cancers-14-02225-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/29ffabd414a6/cancers-14-02225-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/09b5fc9d3fad/cancers-14-02225-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/277f01a18f60/cancers-14-02225-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e546/9099575/256f6c01b0c9/cancers-14-02225-g004.jpg

相似文献

1
Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival.通过组织微阵列分析筛查转移性肾上腺皮质癌的预后生物标志物，确定P53为总生存期的独立预后标志物。
Cancers (Basel). 2022 Apr 29;14(9):2225. doi: 10.3390/cancers14092225.
2
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.III-IV 期肾上腺皮质癌（ACC）的预后因素：一项欧洲肾上腺肿瘤研究网络（ENSAT）的研究。
Ann Oncol. 2015 Oct;26(10):2119-25. doi: 10.1093/annonc/mdv329.
3
Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study.基于 DNA 生物标志物对肾上腺皮质癌分类的性能：一项预后研究。
Eur J Endocrinol. 2023 Aug 2;189(2):262-270. doi: 10.1093/ejendo/lvad112.
4
Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.累积 GRAS 评分作为肾上腺皮质癌切除术后生存的预测指标：来自美国肾上腺皮质癌数据库的分析。
Ann Surg Oncol. 2021 Oct;28(11):6551-6561. doi: 10.1245/s10434-020-09562-8. Epub 2021 Feb 14.
5
S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study.S-GRAS 评分用于预测肾上腺皮质癌的预后分类：一项国际多中心 ENSAT 研究。
Eur J Endocrinol. 2021 Nov 30;186(1):25-36. doi: 10.1530/EJE-21-0510.
6
The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.“GRAS”参数在I-III期肾上腺皮质癌中的临床应用：来自一家大型机构的长期数据。
Endocrine. 2020 Feb;67(2):449-456. doi: 10.1007/s12020-019-02141-2. Epub 2019 Nov 30.
7
DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.DNA甲基化是肾上腺皮质癌生存的独立预后标志物。
J Clin Endocrinol Metab. 2017 Mar 1;102(3):923-932. doi: 10.1210/jc.2016-3205.
8
Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.晚期肾上腺皮质癌的预后因素：一家国家转诊中心20年经验总结
J Endocr Soc. 2022 Jul 26;6(9):bvac112. doi: 10.1210/jendso/bvac112. eCollection 2022 Sep 1.
9
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.β-连环蛋白的激活与肾上腺皮质癌的特定临床和病理特征以及不良预后相关。
Clin Cancer Res. 2011 Jan 15;17(2):328-36. doi: 10.1158/1078-0432.CCR-10-2006. Epub 2010 Nov 18.
10
Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma.固醇O-酰基转移酶1作为肾上腺皮质癌的预后标志物
Cancers (Basel). 2020 Jan 19;12(1):247. doi: 10.3390/cancers12010247.

引用本文的文献

1
Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining.通过病理特征、免疫组织化学标志物和网状组织化学染色对肾上腺皮质癌进行诊断和预后评估。
Diagn Pathol. 2024 May 27;19(1):71. doi: 10.1186/s13000-024-01496-z.

本文引用的文献

1
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.肾上腺皮质癌和恶性嗜铬细胞瘤：ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2020 Nov;31(11):1476-1490. doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27.
2
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.SOAT1 在肾上腺皮质癌中的表达与米托坦单药治疗反应：ENSAT 多中心研究。
J Clin Endocrinol Metab. 2020 Aug 1;105(8). doi: 10.1210/clinem/dgaa293.
3
Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC.
癌-睾丸抗原FATE1在肾上腺皮质肿瘤中的表达与广泛的自身免疫反应相关，是成人肾上腺皮质癌（ACC）而非儿童ACC恶性肿瘤的标志物。
Cancers (Basel). 2020 Mar 14;12(3):689. doi: 10.3390/cancers12030689.
4
Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.使用 1816 名卵巢癌患者的转录组数据预测铂类和紫杉烷类耐药的生物标志物。
Gynecol Oncol. 2020 Mar;156(3):654-661. doi: 10.1016/j.ygyno.2020.01.006. Epub 2020 Jan 20.
5
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients.替莫唑胺在晚期肾上腺皮质癌患者中的活性和安全性。
Eur J Endocrinol. 2019 Dec;181(6):681-689. doi: 10.1530/EJE-19-0570.
6
Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.分子分类在肾上腺皮质癌预后评估中的价值
JAMA Oncol. 2019 Oct 1;5(10):1440-1447. doi: 10.1001/jamaoncol.2019.1558.
7
Targeted Assessment of Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.靶向甲基化评估鉴定出一种快速复发、常规致命的肾上腺皮质癌分子亚型。
Clin Cancer Res. 2019 Jun 1;25(11):3276-3288. doi: 10.1158/1078-0432.CCR-18-2693. Epub 2019 Feb 15.
8
Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.Fascin-1 是一种与肾上腺皮质癌侵袭性相关的新型预后生物标志物。
J Clin Endocrinol Metab. 2019 May 1;104(5):1712-1724. doi: 10.1210/jc.2018-01717.
9
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.欧洲内分泌学会成人肾上腺皮质癌管理临床实践指南，与欧洲肾上腺肿瘤研究网络合作。
Eur J Endocrinol. 2018 Oct 1;179(4):G1-G46. doi: 10.1530/EJE-18-0608.
10
Clinical and molecular prognostic factors in adrenocortical carcinoma.肾上腺皮质癌的临床和分子预后因素
Minerva Endocrinol. 2019 Mar;44(1):58-69. doi: 10.23736/S0391-1977.18.02900-0. Epub 2018 Sep 12.